GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

GSK Plc, seeking to snatch market share from Gilead Sciences Inc.’s best-selling HIV pill, said its long-acting shot works just as well and lets patients replace the daily medicine with an ...

Low-cost preventative HIV medication may be ready as early as 2026, as British pharmaceutical company GSK strikes a deal allowing developing countries access to generic versions.

LONDON – GlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to ...